A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 700 articles on Celgene.
Top Health Stocks to Buy Now

Why Celgene, Intuitive Surgical, and Vertex Pharmaceuticals rank among the top health stocks to b...

A Strong Case for Buying Celgene

High growth at a reasonable price in a large-capitalization drug stock makes this an unusually at...

The 1 Stock I'd Buy Right Now

In the vast ocean of stocks, big biotech Celgene is the one that looks most attractive to me at t...



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $130.85
Prev Close: $133.85
Open: $133.72
Bid: $130.50
Ask: $131.47
Day's Range: $130.78 - $133.85
52wk Range: $94.42 - $135.18
Volume: 4,481,723
Avg Vol 4,510,892
Market Cap: $102B
P/E (ttm): 50.32
EPS (ttm): $2.66
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2199 Outperform
76 Underperform
CAPS All Stars
 
481 Outperform
13 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

93% Approve

Based on 32 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers